JAK2V617F基因突变与非突变布-加综合征患者介入术后再狭窄对比观察

Postoperative restenosis of Budd-Chiari syndrome after interventional treatment:comparison between patients with JAK2V617F gene mutation and patients with no JAK2V617F gene mutation

目的探讨JAK2V617F基因突变对布-加综合征(BCS)患者介入术后再狭窄的影响。方法回顾性分析2015年1月至2019年9月在徐州医科大学附属医院接受介入术治疗的JAK2V617F基因突变BCS患者(突变组,n=18)和非突变BCS患者(对照组,n=36)临床资料,比较两组患者基线数据和介入术后再狭窄率。结果突变组血小板计数、凝血酶原时间、活化部分凝血活酶时间及国际标准化比值均高于对照组(P<0.05)。突变组介入术后患者再狭窄率显著高于对照组(43.8%对13.9%,P=0.037)。突变组和对照组患者介入术后1、2、3年首次通畅率分别为67.0%、67.0%、40.2%和93.8%、84.0%、78.8%,突变组患者首次通畅率均显著低于对照组(P=0.015)。结论 JAK2V617F基因突变可能增加BCS患者介入术后再狭窄发生率。

Objective To explore the influence of JAK2V617F gene mutation on the occurrence of restenosis in Budd-Chiari syndrome(BCS) patients after receiving interventional treatment. Methods The clinical data of 18 BCS patients with JAK2V617F gene mutation(mutation group) and 36 BCS patients with no JAK2V617F gene mutation(control group), who underwent interventional treatment from January 2015 to September 2019 at the Affiliated Hospital of Xuzhou Medical University of China, were retrospectively analyzed.The baseline data and postoperative restenosis rates were compared between the two groups. Results The platelet count, prothrombin time, partially activated prothrombin time and international standardized ratio in the mutation group were remarkably higher than those in the control group(P<0.05). Restenosis rates in the mutation group and the control group were 43.8% and 13.9% respectively, the difference between the two groups was statistically significant(P=0.037). The overall cumulative 1-, 2-and 3-year primary patency rates in the mutation group were 67.0%, 67.0% and 40.2% respectively, which were strikingly lower than 93.8%, 84.0%and 78.8% respectively in the control group(P=0.015). Conclusion JAK2V617F gene mutation may increase the restenosis rate in BCS patients after receiving interventional treatment.